PredictAD is a European Union funded research project which will study imaging biomarkers (MRI, PET FDG and PET PIB), electrical brain activity measurement and blood based markers (proteomics and metabolomics) and develop methods for how to combine data from different biomarkers. Combining this multi-source information may enable earlier diagnosis of Alzheimer's disease, but may also provide crucial information used for differentiating between various forms of dementia and for assessing disease severity. It may also allow for improved detection of disease progression and treatment efficacy monitoring.
"The aim of PredictAD project is to develop an objective indicator to diagnose Alzheimer's disease at the earliest stage possible. This may be possible by combining data from various data sources of patient monitoring, such as neuropsychological tests, medical imaging, electrical brain activity measurements, and analysing protein and metabolomics levels of blood samples. Early diagnostics may play an important role in effective medical treatment of Alzheimer's disease, especially in the future, as the next generation of more effective therapies become available for all patients", stated the Scientific Co-ordinator of the project, Dr. Jyrki Lötjönen from VTT.
"According to the latest estimates, the global prevalence of Alzheimer's disease is predicted to quadruple to 106 million by 2050. (Forecasting the global burden of Alzheimer's disease. Alzheimer's and Dementia Vol. 3 pp. 186-191, July 2007.) Thus, there is a critical need for effective diagnostic tools to help in the early diagnosis of this debilitating disease", stated Dr. Lennart Thurfjell, Head of Diagnostic Software, Medical Diagnostics at GE Healthcare.
At a later stage during this three-year project, a selected biomarker set will be used to develop an efficient and reliable software solution that can be used by a physician to assess the risk, to diagnose and to monitor the progress of Alzheimer's disease in real clinical conditions using various patient data. The accuracy, usability and cost-effectiveness of the models and software will be clinically evaluated.
Currently, there is no curative treatment for Alzheimer's disease. If new drugs or prevention strategies were proven to be effective, an early diagnosis may enable doctors to provide medical care at an earlier stage, at a time when clinical diagnosis using only signs and symptoms of disease is challenging.
"PredictAD fits perfectly with GE Healthcare's 'Early Health' vision as it will help us gain important knowledge, not only about individual biomarkers, but also about how they may combine for early detection and therapy response monitoring. Improving our understanding of the role that different imaging and non-imaging biomarkers play during the disease process is the key as we strive to develop new diagnostic solutions for Alzheimer's disease", Dr. Thurfjell summed up.
Dementia causes long and oppressive suffering to patients and their relatives, and imposes enormous costs on society. Affecting more than 5 million people in Europe (Alzheimer-Europe), Alzheimer's disease is the most common cause of dementia; it covers 50-70 percent of all dementia cases. Estimated costs of Alzheimer's disease to European society are more than 55 billion euro per annum. (Costs of Disorders of the Brain in Europe. Jes Olesen et al. European Journal of Neurology 12 (Suppl. 1), iii-v.) As the proportion of elderly people in the population is increasing these costs are becoming a real burden to the society. Therefore a major breakthrough in Alzheimer's disease prevention and treatment is vital also in the economical sense.
With a consortium of top-level European research and industrial partners, the PredictAD project takes an important step towards an early approach to Alzheimer's disease prediction and management. Public and private partners from 8 research, academic, industrial and medical organisations from four different European countries will form the research consortium. PredictAD consortium members are VTT Technical Research Centre of Finland, GE Healthcare (United Kingdom), Nextim Ltd. (Finland), University of Kuopio (Finland), Imperial College London (United Kingdom), Uppsala University (Sweden), University of Milan (Italy) and Rigshospitalet (Denmark).
VTT Technical Research Centre of Finland is a contract research organisation involved in many international assignments. With its more than 2800 employees, VTT provides a wide range of technology and applied research services for its clients, private companies, institutions and the public sector. VTT is striving to improve the well-being of society and to enhance the technical and economic performance of its clients.
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Its expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.
GE Healthcare's broad range of products and services enable health care providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Its vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company. Worldwide, GE Healthcare employs more than 46.000 people committed to serving health care professionals and their patients in more than 100 countries. More company news is available in the VMW April 2008 article GE Healthcare launches diagnostic advancements on premier women's health ultrasound system.